Jump to main content
Jump to site search


Maternal SSRIs Experience and Risk of ASD in Offspring’s: A Review

Abstract

Antidepressants are extensively used during pregnancy is associated with severe outcomes, including innate malformations, prematurity, and low birth weight etc. A recent study suggested that prenatal exposure to antidepressants may impair child neurodevelopment process. Thus, the aim of this review is to investigate the potential association between prenatal use of selective serotonin reuptake inhibitors (SSRIs) and the risk of autism spectrum disorders (ASDs). Twelve studies related to the linkage between SSRI exposure during pregnancy and ASD in children were explored and compiled. Though, there is a knowledge gap concerning the potential link between gestational exposure to antidepressants and the risk of ASDs. Despite such limitations, available data showed that some signal exists and signifying that antenatal exposure to SSRIs may increase the risk of ASDs. Thus, there is a vital need for further, large and well-designed research to definitively evaluate the existence and the magnitude of this severe risk.

Back to tab navigation

Publication details

The article was received on 05 Apr 2018, accepted on 09 Jul 2018 and first published on 11 Jul 2018


Article type: Review Article
DOI: 10.1039/C8TX00102B
Citation: Toxicol. Res., 2018, Accepted Manuscript
  •   Request permissions

    Maternal SSRIs Experience and Risk of ASD in Offspring’s: A Review

    Z. fatima, A. zahra, M. ghouse, L. Yang, X. Wang and Z. yuan, Toxicol. Res., 2018, Accepted Manuscript , DOI: 10.1039/C8TX00102B

Search articles by author

Spotlight

Advertisements